Skip to content
February 23, 2026

FDA Grants Reunion’s RE104 Breakthrough Therapy Designation in Postpartum Depression

You are about to leave MPM BioImpact's website. MPM BioImpact is not responsible for the content on other companies' websites.

Cancel Continue